Skip to main content

Monjuvi

Pronunciation: mon-JOO-vee
Generic name: tafasitamab
Dosage form: single-dose vial for intravenous infusion (200 mg)
Drug class: CD19 monoclonal antibodies

Medically reviewed by Carmen Pope, BPharm. Last updated on Jun 23, 2025.

What is Monjuvi?

Monjuvi is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or relapsed or refractory follicular lymphoma (FL). It is given as an intravenous infusion by a healthcare provider, two to five times during a 28-day cycle.

Monjuvi is a targeted immunotherapy treatment that works by binding to CD19 markers expressed on the surface of pre-B and mature-B lymphocytes and several B-cell cancers, including DLBCL and FL. Once bound, Monjuvi signals the immune system to attack and destroy these cells. Monjuvi belongs to the drug class called  CD19-directed cytolytic antibodies.

Monjuvi (tafasitamab-cxix) gained FDA approval on July 31, 2020, for DLBCL. Approval was extended on June 18, 2025, to include FL. There is no generic.

FDA approvals and uses

Monjuvi is FDA approved for adults with:

Monjuvi FDA approval was granted to Incyte and MorphoSys AG based on the following positive results from the clinical trial L-MIND (NCT02399085), an open-label Phase 2 study, which reported

Side effects

The most common side effects of Monjuvi when given with lenalidomide in DLBCL are:

The most common side effects of Monjuvi when given with lenalidomide and rituximab in FL are:

Warnings and serious side effects 

Monjuvi may cause the following serious side effects:

As with any medication, allergic reactions may happen. Get emergency medical help if you have signs of an allergic reaction to Monjuvi: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Monjuvi may harm an unborn baby. Use effective birth control to prevent pregnancy while using Monjuvi and for at least 3 months after your last dose. Carefully follow all instructions about the use of birth control while you are using Monjuvi in combination with lenalidomide.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking

Before you receive Monjuvi, tell your healthcare provider about all of your medical conditions, including if you:

Pregnancy

Monjuvi may harm your unborn baby. You should not become pregnant during treatment with Monjuvi. Do not receive treatment with Monjuvi in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.

Monjuvi is used in combination with lenalidomide. Both men and women using lenalidomide must use effective birth control. Even one dose can cause severe, life-threatening birth defects or death of a baby if the mother or the father is taking lenalidomide at the time of conception or during pregnancy. You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, blood and sperm donation.

Breastfeeding

 It is not known if Monjuvi passes into your breastmilk. Do not breastfeed during treatment and for at least 3 months after your last dose of Monjuvi.

How is Monjuvi given?

Monjuvi will be given to you by your healthcare provider as an intravenous (IV) infusion into one of your veins.

Each treatment cycle of Monjuvi lasts for 28 days.

Dosing information

Adult Dose of Monjuvi for DLBCL 

 The recommended dosage is 12 mg/kg as an IV infusion according to the following dosing schedule.

Administer Monjuvi in combination with lenalidomide for a maximum of 12 cycles and then continue Monjuvi as monotherapy until disease progression or unacceptable toxicity occurs.

Adult Dose of Monjuvi for FL 

 The recommended dosage is 12 mg/kg as an IV infusion according to the following dosing schedule.

Administer Monjuvi in combination with lenalidomide (Cycles 1 to 12) and rituximab (Cycles 1 to 5). 

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your Monjuvi injection.

What other drugs will affect this medicine?

Other drugs may interact with Monjuvi, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 

Does Monjuvi interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Ingredients

Active ingredient: tafasitamab-cxix.

Inactive ingredients: citric acid monohydrate, polysorbate 20, sodium citrate dihydrate, and trehalose dihydrate.

Monjuvi is supplied as 200 mg of tafasitamab-cxix as lyophilized powder in a single-dose vial for reconstitution.

Company

Monjuvi is manufactured by the Incyte Corporation, located in Wilmington, DE 19803.

Monjuvi Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Monjuvi.

Monjuvi (tafasitamab-cxix) - MorphoSys US Inc.
Formulation type Strength
Single-Dose Vial 200 mg

Popular FAQ

How does Monjuvi work?

Monjuvi (tafasitamab-cxix injection) is a targeted immunotherapy drug and works by helping the immune system find and kill cancer cells in people living with advanced diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).

Continue reading
How is Monjuvi given / administered?

Monjuvi (tafasitamab-cxix) is given by a healthcare provider as an intravenous (IV) infusion using a needle inserted into a vein. You will receive it plus any premedications at a clinic or infusion center. Your first IV infusion will take about 1.5 to 2.5 hours; thereafter, your infusions will usually take 1.5 to 2 hours. You may need to be at the clinic for a longer period of time for preparation and observation.

Continue reading
What is the success rate of Monjuvi?

Studies have shown an overall response rate of 55% in adults (39 of 71) with advanced diffuse large B-cell lymphoma (DLBCL) who received Monjuvi treatment (plus lenalidomide) for up to 12 cycles. Patients receiving Monjuvi in combination with rituximab and lenalidomide for R/R follicular lymphoma achieved a median PFS of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared to 13.9 months (95% CI, 11.5-16.4) in the placebo control arm.

Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.